profit from every $100 of sales.
$0$100
Lantern Pharma
$0.43-6.07% today
-87.5% in 1 year
1-year low $0.431-year high $4.17
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Lantern Pharma sold, what it kept, and what it did with the cash.
Sales went from $0 in 2022 to $0 in 2025, with -$17.1 million of profit last year.
SalesProfit
Lantern Pharma vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Lantern Pharma | No profit yet | ||
 Vertex Pharmaceuticals | 34.5× · Expensive | ||
 Regeneron Pharmaceuticals | 21.9× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.0× · Fair price |
AI analysis
An AI analyst reads Lantern Pharma's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 0 | 0 | 0 | 0 | |
| – | – | – | – | |
| -14 | -18 | -22 | -18 | |
| -14 | -18 | -22 | -18 | |
| -14 | -16 | -21 | -17 | |
| -1.31 | -1.47 | -1.93 | -1.57 | |
| – | – | – | – | |
| – | – | – | – | |
| – | – | – | – |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 59 | 44 | 26 | 11 |
| Cash | 37 | 22 | 8 | 4 |
| Total debt | 0 | 0 | 0 | 0 |
| Total liabilities | 3 | 3 | 4 | 5 |
| 56 | 41 | 21 | 7 | |
| 11 | 11 | 11 | 11 | |
| -20.3% | -34.3% | -81.9% | -214.8% | |
| -25.4% | -39.0% | -98.1% | -262.0% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -13 | -14 | -18 | -16 | |
| 0 | 0 | 0 | 0 | |
| -13 | -14 | -18 | -16 | |
| Dividends paid | – | – | – | – |
| 2 | 0 | – | – | |
| 1 | 1 | 1 | 1 |
Valuation
- –
- –
- –
- 10.4×
- –
- –
- –
- -242.4%
- -264.7%
- 0.0%
Profitability
- 0.0%
- 0.0%
- 0.0%
- 0.0%
- -473.9%
- -35.7%
- -1.0%
- -220.3%
- -482.0%
- –
Growth
- –
- –
- +12.0%
- –
- −0.0%
Financial health
- 0.3×
- 0.02
- 0.8%
- –
- 1.87
- 1.87
- 0.00
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 19%of 898
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 15, 2026 | -0.30 | -0.36 | +16.7% |
| Mar 30, 2026 | -0.36 | -0.46 | +21.7% |
| Nov 12, 2025 | -0.39 | -0.46 | +15.2% |
| Aug 13, 2025 | -0.40 | -0.53 | +24.5% |
| May 15, 2025 | -0.42 | -0.49 | +14.3% |
| Mar 27, 2025 | -0.54 | -0.51 | −5.9% |
| Nov 7, 2024 | -0.42 | -0.56 | +25.0% |
| Aug 8, 2024 | -0.46 | -0.55 | +16.4% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
34No pass
Benjamin Graham
33No pass
Philip Fisher
39No pass
Peter Lynch
60Pass
Joel Greenblatt
0No pass
Charlie Munger
33No pass
Terry Smith
33No pass
Questions about Lantern Pharma
Is Lantern Pharma a good stock to buy?
A business with weak numbers that is not profitable yet. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Lantern Pharma AI analysis
What does Lantern Pharma do?
Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. It is in Biotechnology.
Does Lantern Pharma pay a dividend?
No. Lantern Pharma does not pay a dividend at the moment.
Is Lantern Pharma stock halal?
No. Lantern Pharma does not pass our halal screen: its cash and confirmed interest-bearing investments are 68% of its market value, at or above the 33% limit. How we check
How has Lantern Pharma stock done over the past year?
Down 87.5% over the past twelve months, to $0.43. It traded between $0.43 and $4.17 and is 89.6% below its high.
Who are Lantern Pharma's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with Lantern Pharma's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.